It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.
Participant is willing and able to give informed consent for participation in the study;
Patients with new diagnosis and/or relapse/s of primary or secondary B-ALL;
Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements;
Participant is willing and able to give informed consent for participation in the study;
Age < 18 years;
B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements.